Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Substance K Receptor Treatment Pipeline Review H2 2016

Wednesday, October 26, 2016 5:41
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Pipeline Review, H2 2016’, provides in depth analysis on Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics development and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/711797-substance-k-receptor-nk2-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) 
- The report reviews Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 

 

 

Complete report details @ https://www.wiseguyreports.com/reports/711797-substance-k-receptor-nk2-review-h2-2016                

Key points in table of content

Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 Report Coverage 5 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) Overview 6 
Therapeutics Development 7 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Products under Development by Stage of Development 7 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Products under Development by Therapy Area 8 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Products under Development by Indication 9 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Pipeline Products Glance 10 
Late Stage Products 10 
Early Stage Products 11 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Products under Development by Companies 12 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Therapeutics Assessment 14 
Assessment by Monotherapy/Combination Products 14 
Assessment by Mechanism of Action 15 
Assessment by Route of Administration 17 
Assessment by Molecule Type 18 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Companies Involved in Therapeutics Development 20 
A. Menarini Industrie Farmaceutiche Riunite Srl 20 
Albireo AB 21 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Drug Profiles 22 
A-3914 – Drug Profile 22 
Product Description 22 
Mechanism Of Action 22 
R&D Progress 22 
A-5425 – Drug Profile 23 
Product Description 23 
Mechanism Of Action 23 
R&D Progress 23 
DTI-100 – Drug Profile 24 
Product Description 24 
Mechanism Of Action 24 
R&D Progress 24 
ibodutant – Drug Profile 25 
Product Description 25 
Mechanism Of Action 25 
R&D Progress 25 
nepadutant – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
Small Molecules to Antagonize NK 1 and NK 2 Receptors for Pain – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Dormant Projects 28 
Substance K Receptor (NK2 Receptor or Neurokinin A Receptor or Tachykinin Receptor 2 or NK2R or TACR2) – Discontinued Products 30 
Appendix 31 
Methodology 31 
Coverage 31 
Secondary Research 31 
Primary Research 31 
Expert Panel Validation 31 
Contact Us 31 
Disclaimer 32

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=711797

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.